RxDoctor Payments Data

Dmitry Shtrambrand, MD

Internal Medicine · West Nyack, NYNPI 1174578165

Payments from drug & device makers

$963in general payments, 2019–2025

Across 33 payments — averaging $29.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$253
  • Supernus Pharmaceuticals, Inc.$125
  • Otsuka America Pharmaceutical, Inc.$125
  • Novo Nordisk$88
  • Amgen$77
  • GSK$51
  • plus $244 from 9 others

What the payments were for

  • Food & beverage$963100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$963 in reported general payments places this provider in the 70th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$116,293
Medicare patients
342
Services billed
900

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin36$43,396
EliquisApixaban24$28,231
RybelsusSemaglutide12$11,437
ZenpepLipase/Protease/Amylase12$8,160
OxycontinOxycodone Hcl14$8,063
Janumet XrSitagliptin Phos/Metformin Hcl11$8,024
Fluticasone-SalmeterolFluticasone Propion/Salmeterol15$2,200
Atorvastatin Calcium245$1,440
Rosuvastatin Calcium100$1,340
Omeprazole55$1,259
Tamsulosin Hcl81$1,179
Levothyroxine Sodium93$1,090
Albuterol Sulfate HfaAlbuterol Sulfate32$1,084
Amlodipine Besylate188$1,012
Celecoxib25$979

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$21$43,39636 claims
PfizerEliquis$15$28,23124 claims
Novo NordiskRybelsus$88$11,43712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in West Nyack

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →